Table 3 Relationship of circulating unadjusted geometric mean concentrations of IGF-I and IGFP-1–7 (ng/mL) with select participant characteristics in postmenopausal women
Characteristics | N | IGF-I | IGFBP-1 | IGFBP-2 | IGFBP-3 | IGFBP-4 | IGFBP-5 | IGFBP-6 | IGFBP-7 |
Mean1 (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | ||
Age at biopsy (years) | |||||||||
<55 | 30 | 105 (94–116) | 0.66 (0.09–1.23) | 335 (271–398) | 3563 (3248–3878) | 150 (135–165) | 388 (357–420) | 184 (166–201) | 113 (106–121) |
55–59 | 38 | 111 (101–121) | 0.40 (0.09–0.72) | 333 (275–392) | 3578 (3370–3787) | 159 (145–172) | 416 (384–447) | 164 (150–177) | 115 (110–121) |
≥ 60 | 35 | 92 (81–103) | 0.94 (0.42–1.63) | 333 (278–388) | 3340 (3027–3652) | 159 (147–170) | 377 (348–405) | 181 (168–194) | 121 (114–128) |
p trend (p het) | 0.67 (0.03) | 0.51 (0.32) | 0.97 (0.99) | 0.26 (0.40) | 0.38 (0.61) | 0.54 (0.18) | 0.87 (0.10) | 0.08 (0.20) | |
Education | |||||||||
≤ High school grad/GED | 22 | 108 (93–124) | 3.13 (1.88-4.37) | 287 (221–353) | 3694 (3383–4005) | 167 (147–186) | 398 (356–440) | 173 (155–192) | 119 (107–131) |
Some college/tech school | 19 | 105 (93–118) | 2.79 (1.81-3.78) | 314 (252–375) | 3389 (3031–3748) | 151 (136–166) | 415 (379–451) | 191 (165–216) | 116 (107–126) |
≥ College graduate | 62 | 100 (92–108) | 3.42 (2.68-4.15) | 359 (311–406) | 3453 (3236–3670) | 154 (145–164) | 386 (363–409) | 171 (162–181) | 116 (113–120) |
p trend (p het) | 0.31 (0.59) | 0.56 (0.67) | 0.07 (0.20) | 0.33 (0.44) | 0.29 (0.39) | 0.46 (0.50) | 0.58 (0.25) | 0.65 (0.88) | |
Body mass index (kg/m2) | |||||||||
< 25 | 41 | 104 (95–112) | 1.62 (0.61–2.63) | 446 (397–494) | 3343 (3154–3532) | 141 (130–153) | 396 (371–421) | 166 (154–177) | 114 (110–119) |
25.0–29.9 | 31 | 103 (91–114) | 0.83 (0.20–1.47) | 323 (263–383) | 3631 (3328–3934) | 168 (153–182) | 388 (354–423) | 179 (164–193) | 112 (106–118) |
≥ 30 | 31 | 101 (87–115) | 0.13 (0.03–0.23) | 235 (194–276) | 3554 (3183–3926) | 166 (155–177) | 398 (362–433) | 185 (166–203) | 125 (117–133) |
p trend (p het) | 0.78 (0.96) | < 0.0001 (< .0001) | < 0.0001 (< .0001) | 0.25 (0.30) | 0.005 (0.004) | 0.95 (0.92) | 0.06 (0.16) | 0.03 (0.02) | |
Age at menarche (years) | |||||||||
≤ 12 | 42 | 105 (97–112) | 0.44 (0.11–0.76) | 317 (262–371) | 3587 (3352–3821) | 157 (146–168) | 389 (363–416) | 180 (166–194) | 114 (109–119) |
13 | 34 | 99 (86–111) | 0.89 (0.17–1.61) | 374 (311–436) | 3365 (3055–3675) | 149 (136–161) | 392 (360–423) | 176 (164–188) | 120 (114–126) |
≥ 14 | 26 | 109 (96–122) | 0.63 (0.09–1.17) | 315 (256–374) | 3558 (3259–3858) | 163 (144–181) | 409 (371–447) | 166 (147–184) | 117 (108–126) |
p trend (p het) | 0.72 (0.46) | 0.45 (0.44) | 0.87 (0.32) | 0.76 (0.48) | 0.71 (0.38) | 0.43 (0.68) | 0.19 (0.41) | 0.40 (0.44) | |
Age at first birth (years) | |||||||||
Nulliparous/ ≥ 30 years | 37 | 108 (98–118) | 0.54 (0.11–0.97) | 359 (300–418) | 3588 (3351–3825) | 151 (137–165) | 388 (357–419) | 178 (163–193) | 116 (111–122) |
< 30 years | 66 | 100 (92–108) | 0.67 (0.29–1.05) | 320 (279–361) | 3438 (3225–3650) | 159 (150–168) | 397 (376–419) | 174 (163–184) | 117 (112–122) |
p het | 0.24 | 0.64 | 0.29 | 0.39 | 0.30 | 0.63 | 0.64 | 0.82 | |
Parity | |||||||||
Nulliparous (0) | 22 | 103 (89–116) | 0.43 (− 0.02–0.89) | 326 (253–398) | 3542 (3197–3888) | 160 (140–180) | 365 (334–395) | 187 (167–208) | 118 (110–125) |
1 | 20 | 105 (90–119) | 0.71 (− 0.09–1.52) | 326 (244–408) | 3468 (3151–3785) | 152 (135–168) | 417 (375–458) | 171 (151–192) | 113 (107–119) |
2 | 42 | 99 (88–110) | 0.76 (0.24–1.29) | 338 (288–389) | 3445 (3150–3739) | 163 (153–173) | 393 (366–420) | 179 (168–190) | 121 (114–128) |
≥ 3 | 19 | 110 (99–120) | 0.51 (−0.05–1.06) | 341 (255–428) | 3559 (3278–3841) | 142 (125–160) | 408 (356–460) | 158 (138–178) | 111 (104–118) |
p trend (p het) | 0.78 (0.71) | 0.72 (0.80) | 0.72 (0.99) | 0.95 (0.95) | 0.40 (0.23) | 0.23 (0.27) | 0.09 (0.15) | 0.71 (0.17) | |
Characteristics | N | IGF-I | IGFBP-1 | IGFBP-2 | IGFBP-3 | IGFBP-4 | IGFBP-5 | IGFBP-6 | IGFBP-7 |
Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | ||
Oral contraceptive use | |||||||||
Never | 15 | 90 (77–103) | 1.14 (−0.04–2.32) | 291 (230–352) | 3214 (2799–3630) | 164 (138–190) | 414 (374–454) | 175 (151–199) | 117 (109–126) |
Former | 88 | 105 (98–112) | 0.56 (0.27–0.84) | 342 (303–380) | 3540 (3367–3714) | 155 (147–163) | 391 (371–410) | 175 (166–184) | 117 (113–121) |
p het | 0.08 | 0.29 | 0.28 | 0.15 | 0.41 | 0.38 | 0.99 | 0.89 | |
Menopausal hormone use | |||||||||
Never | 67 | 101 (93–110) | 0.65 (0.28–1.01) | 329 (287–372) | 3464 (3270–3659) | 159 (149–168) | 392 (371–413) | 174 (164–184) | 116 (111–121) |
Former | 36 | 105 (96–115) | 0.57 (0.11–1.03) | 342 (287–398) | 3541 (3252–3830) | 152 (139–165) | 398 (365–431) | 177 (161–193) | 118 (113–124) |
p het | 0.55 | 0.81 | 0.72 | 0.66 | 0.40 | 0.75 | 0.79 | 0.60 | |
Family history of breast cancer in a first-degree relative | |||||||||
None | 75 | 103 (97–110) | 0.53 (0.24–0.83) | 333 (295–371) | 3490 (3321–3660) | 155 (146–164) | 391 (371–412) | 172 (162–182) | 117 (112–121) |
1 or more | 27 | 102 (86–118) | 0.90 (0.13–1.67) | 344 (270–418) | 3469 (3073–3865) | 160 (145–174) | 404 (366–441) | 184 (167–200) | 117 (111–123) |
p het | 0.83 | 0.33 | 0.78 | 0.91 | 0.59 | 0.55 | 0.26 | 0.88 | |
Age at menopause | |||||||||
< 45 | 17 | 95 (77–113) | 0.91 (− 0.01–1.84) | 287 (208–367) | 3389 (2996–3783) | 168 (143–193) | 411 (378–444) | 181 (158–203) | 118 (111–126) |
45–49 | 26 | 114 (103–126) | 0.40 (0.02–0.79) | 305 (245–365) | 3585 (3257–3913) | 153 (140–166) | 415 (377–453) | 164 (148–180) | 119 (109–130) |
≥ 50 | 48 | 105 (97–112) | 0.57 (0.18–0.96) | 351 (300–402) | 3607 (3411–3803) | 153 (142–165) | 380 (353–407) | 180 (168–193) | 115 (111–120) |
p trend (p het) | 0.53 (0.11) | 0.67 (0.54) | 0.14 (0.32) | 0.36 (0.58) | 0.28 (0.42) | 0.14 (0.23) | 0.70 (0.28) | 0.48 (0.69) | |
Cigarette smoking | |||||||||
Never | 37 | 103 (91–116) | 0.68 (0.16–1.21) | 357 (296–418) | 3491 (3144–3838) | 157 (145–168) | 387 (358–416) | 184 (168–201) | 119 (113–124) |
Former | 47 | 105 (97–114) | 0.40 (0.12–0.68) | 296 (250–342) | 3546 (3371–3722) | 155 (144–167) | 418 (391–444) | 174 (164–184) | 117 (112–122) |
Current | 11 | 89 (71–108) | 2.60 (−0.06–5.25) | 382 (297–466) | 3167 (2789–3544) | 178 (151–204) | 355 (307–402) | 149 (125–173) | 113 (93–133) |
p trend (p het) | 0.39 (0.31) | 0.45 (0.06) | 0.66 (0.16) | 0.45 (0.36) | 0.29 (0.25) | 0.87 (0.07) | 0.02 (0.04) | 0.43 (0.70) | |
Breast biopsy prior to enrollment | |||||||||
Never | 62 | 102 (94–109) | 0.67 (0.26–1.08) | 344 (300–387) | 3429 (3251–3607) | 158 (148–168) | 404 (384–425) | 175 (163–186) | 115 (112–119) |
Ever | 39 | 105 (93–117) | 0.50 (0.13–0.87) | 313 (258–369) | 3610 (3287–3933) | 156 (144–167) | 379 (346–412) | 177 (163–190) | 119 (112–127) |
p het | 0.66 | 0.55 | 0.39 | 0.30 | 0.76 | 0.18 | 0.84 | 0.32 | |
Biopsy diagnosis | |||||||||
Benign non-proliferative | 31 | 103 (93–113) | 0.94 (0.19–1.68) | 369 (313–426) | 3556 (3282–3830) | 152 (137–166) | 409 (379–439) | 169 (152–186) | 114 (107–121) |
Proliferative with/without atypia | 47 | 103 (92–114) | 0.47 (0.13–0.80) | 307 (257–356) | 3499 (3237–3760) | 163 (151–175) | 381 (353–409) | 180 (168–192) | 121 (115–127) |
In-situ/invasive | 25 | 103 (91–114 s) | 0.63 (0.05–1.21) | 345 (271–418) | 3397 (3097–3698) | 149 (136–162) | 401 (368–433) | 175 (159–191) | 112 (107–117) |
p trend (p het) | 0.95 (0.99) | 0.49 (0.46) | 0.55 (0.29) | 0.49 (0.78) | 0.87 (0.28) | 0.67 (0.39) | 0.57 (0.56) | 0.75 (0.12) | |